Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.85 USD | -1.79% | -2.37% | -52.57% |
05-10 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
05-10 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.57% | 2.45B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.11% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Morgan Stanley Upgrades ACADIA Pharmaceuticals to Overweight From Equalweight, Raises Price Target to $40 From $31